Federal Register / Vol. 72, No.
221 / Friday, November 16, 2007 / Notices
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22488 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 24,
2007, JFC Technologies, LLC., 100 W.
Main Street, Bound Brook, New Jersey
08805, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug Schedule
Diphenoxylate (9170) ................... II
Hydrocodone (9193) ..................... II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than January 15, 2008.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
mstockstill on PROD1PC66 with NOTICES
Administration.
[FR Doc. E7–22520 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005 21:48 Nov 15, 2007 Jkt 214001
64681
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 3, 2007, (72 FR 36482), Johnson
Matthey Inc., Custom Pharmaceuticals
Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066–1742, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Cocaine (9041) .............................
Ecgonine (9180) ...........................
The company plans on producing
cocaine for sale to its customers, who
are final dosage manufacturers. The
ecgonine is formed during the
manufacturing process for cocaine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22478 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
PO 00000 Frm 00108 Fmt 4703 Sfmt 4703
July 5, 2007, (72 FR 36727), Abbott
Laboratories, DBA Knoll Pharmaceutical
Company, 30 North Jefferson Road,
Whippany, New Jersey 07981, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug Schedule
Dihydromorphine (9145) ............... I
Hydromorphone (9150) ................ II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
Schedule No comments or objections have been
received. DEA has considered the
II factors in 21 U.S.C. 823(a) and
II determined that the registration of
Abbott Laboratories to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Abbott Laboratories to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22476 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36729–36730), Lin
Zhi International Inc., 687 North
Pastoria Avenue, Sunnyvale, California
94085, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
E:\FR\FM\16NON1.SGM 16NON1
 64682 Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
Drug
Tetrahydrocannabinols (7370) .....
3,4-
Methylenedioxymethamphetam-
ine (7405)
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk, (9273)
Morphine (9300) ...........................
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22479 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 3, 2007, (72 FR 36483), Lonza
Riverside, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
mstockstill on PROD1PC66 with NOTICES
I and II:
Drug
Gamma hydroxybutyric acid
(2010).
VerDate Aug<31>2005 21:48 Nov 15, 2007 Jkt 214001
Schedule Drug
I Amphetamine (1100) ....................
I Methylphenidate (1724) ................
The company plans to manufacture
II
bulk products for finished dosage units
II
II and distribution to its customers.
II No comments or objections have been
II received. DEA has considered the
II factors in 21 U.S.C. 823(a) and
determined that the registration of
Lonza Riverside to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lonza Riverside to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above-named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22485 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 5, 2007,
National Center for Natural Products
Research—NIDA MProject, University of
Mississippi, 135 Coy Waller Lab
Complex, University, Mississippi 38677,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
The company plans to cultivate
I marihuana for the National Institute on
Drug Abuse for research approved by
PO 00000 Frm 00109 Fmt 4703 Sfmt 4703
Schedule the Department of Health and Human
Services.
II Any other such applicant and any
II person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than January 15, 2008.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22518 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36730), Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug Schedule
Tetrahydrocannabinols (7370) ..... I
Methylphenidate (1724) ................ II
Codeine (9050) ............................. II
Dihydrocodeine (9120) ................. II
Oxycodone (9143) ........................ II
Hydromorphone (9150) ................ II
Hydrocodone (9193) ..................... II
Thebaine (9333) ........................... II
Oxymorphone (9652) ................... II
Noroxymorphone (9668) .............. II
Fentanyl (9801) ............................ II
Schedule The company plans to manufacture
the listed controlled substances in bulk
I for conversion and sale to dosage form
I manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
E:\FR\FM\16NON1.SGM 16NON1